Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Unraveling the Role of Earthworms in Enhancing Mineral Weathering for CO2 Removal
Published on: November 10, 2023
Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity
Richa Shrivastava1, Shruti Trivedi2, Pankaj Kumar Singh3
1Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India; Academy of Scientific and Innovative Research, (AcSIR), New Delhi, 110025, India.
Abstract:
Breast cancer is most frequently diagnosed cancer and fifth leading cause of death in women. About 20-30% of all breast cancers overexpress HER2/neu receptors. Lapatinib is a dual tyrosin kinase inhibitor of EGFR and HER2. It exhibits its anticancer effect via blocking intracellular domain of HER2 receptor in breast cancer. Lapatinib belongs to class II of BSC classification due to its poor solubility restricting its clinical application. Due to presence of HER2 receptor on cardiomyocytes, it is associated with generation of cardiotoxicity. The present study was aimed to design a PEGylated liposomal formulation of Lapatinib and evaluate its anticancer potential. Lapatinib liposomes were prepared using lipid layer hydration method and its characterization was done by determining its particle size, zeta potential, entrapment efficiency and in vitro release profiling. The anti-tumor activity of PEGylated liposomal formulation was evaluated in xenografted tumor induced by MDA-MB-453 breast cancer cells in chick embryos. The anti-tumor effect of lapatinib was enhanced by its PEGylated liposomal preparation as it led to the reduction in tumor size to a greater extent compared to the embryos treated with free lapatinib. Flowcytometric analysis and immunoflurescence study using cleaved PARP antibody demonstrated the enhanced apoptotic potential of PEGylated liposomes of lapatinib. SGOT levels, marker for cardiotoxicity and hepatotoxicity, significantly decreased in serum of embryos treated with PEGylated liposomes of lapatinib compared to free drug treated embryos. Hence, the PEGylated liposomal formulation of lapatinib can be used as a therapeutic strategy against HER2 positive breast cancer either alone or in combination with conventional anticancer agents and hormonal therapies.
Insights
This study developed PEGylated liposomal Lapatinib to improve breast cancer treatment. The new formulation enhanced anti-tumor effects and reduced cardiotoxicity compared to free Lapatinib.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Breast cancer is a leading cause of death in women, with HER2/neu receptor overexpression in 20-30% of cases.
- Lapatinib, a dual tyrosine kinase inhibitor, targets EGFR and HER2 but faces clinical limitations due to poor solubility (Class II BSC) and cardiotoxicity.
- HER2 receptors on cardiomyocytes contribute to Lapatinib-induced cardiotoxicity.
Purpose of the Study:
- To design and characterize a PEGylated liposomal formulation of Lapatinib.
- To evaluate the enhanced anticancer potential and reduced cardiotoxicity of this novel formulation.
- To investigate the anti-tumor mechanisms, including apoptosis induction.
Main Methods:
- Lapatinib liposomes were prepared using the lipid layer hydration method.
- Formulation characterization included particle size, zeta potential, entrapment efficiency, and in vitro release profiling.
- Anticancer efficacy and cardiotoxicity were assessed in chick embryo xenograft models (MDA-MB-453 cells), with flow cytometry and immunofluorescence used for apoptosis analysis.
Main Results:
- PEGylated liposomal Lapatinib significantly reduced tumor size compared to free Lapatinib.
- Enhanced apoptotic potential was confirmed via flow cytometry and cleaved PARP antibody staining.
- Serum SGOT levels, a marker for cardiotoxicity and hepatotoxicity, were significantly decreased in the liposomal Lapatinib group.
Conclusions:
- PEGylated liposomal Lapatinib demonstrates enhanced anti-tumor activity and reduced cardiotoxicity.
- This formulation represents a promising therapeutic strategy for HER2-positive breast cancer.
- It can be used as a standalone treatment or in combination with other therapies.
More Related Videos
07:47Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
Published on: December 13, 2015
09:51Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes
Published on: March 3, 2020
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Group Design
Depolarizing Blockers: Pharmocokinetics
Factorial Design
Self-Evaluation: Self-Enhancement and Self-Verification
Cartesian Form for Vector Formulation